Summary by Futu AI
The Securities and Exchange Commission (SEC) has notified Cardio Diagnostics that it will not review the company's Form S-3 Registration Statement filed on February 7, 2025. The communication was addressed to CEO Meeshanthini Dogan at the company's Chicago headquarters.The SEC emphasized that the company and its management remain responsible for ensuring the accuracy and adequacy of their disclosures, regardless of the SEC staff's review status, comments, or actions. The decision aligns with standard SEC procedures under Rules 460 and 461 regarding acceleration requests.
Comment(0)
Reason For Report